Briacell Therapeutics
BCTX
About: BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Employees: 12
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
93% more capital invested
Capital invested by funds: $94.1K [Q1] → $181K (+$87.3K) [Q2]
15% more funds holding
Funds holding: 13 [Q1] → 15 (+2) [Q2]
0.03% more ownership
Funds ownership: 0.07% [Q1] → 0.1% (+0.03%) [Q2]
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
HC Wainwright & Co.
Emily Bodnar
|
$40
|
Buy
Maintained
|
27 Aug 2025 |
Financial journalist opinion
Based on 4 articles about BCTX published over the past 30 days
